EP
MLTX icon

Essential Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Essential Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.97K Sell
168
-542
-76% -$8.86K ﹤0.01% 1920
2026
Q2 		$13.8K Buy
710
+702
+8,775% +$12.7K 0.01% 1063
2026
Q1 		$149 Buy
+8
New +$133 ﹤0.01% 2658

Other funds holding MLTX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
BWM
BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return
BC
Bulwark Capital Fernandina Beach, Florida $189M AUM 7.81% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's MLTX Position: Q3 2026 in Review

Essential Partners reduced its MoonLake Immunotherapeutics (MLTX) stake by 76% in Q3 2026, selling an estimated $8.86K and leaving 168 shares worth $1.97K. The position accounts for ﹤0.01% of the portfolio, ranked #1920.

Essential Partners first reported a position in MLTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $13.8K in Q2 2026. 10 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Essential Partners held 168 shares of MoonLake Immunotherapeutics worth $1.97K as of Q3 2026.
  • Essential Partners sold 542 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $8.86K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1920 holding.
  • Essential Partners first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Essential Partners's MoonLake Immunotherapeutics position peaked at $13.8K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.